• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Anika inks $350k settlement with former CMO Mascioli, hits $5m milestone

July 18, 2017 By Sarah Faulkner

Anika TherapeuticsAnika Therapeutics (NSDQ:ANIK) said last week that it agreed to pay former chief medical officer Dr. Stephen Mascioli $350,000 “for all alleged damages and attorneys’ fees.” In return, Mascioli agreed not to pursue legal action against the Bedford, Mass.-based company.

Mascioli departed from Anika in January this year, after spending less than a year there.

According to a regulatory filing, the company and Mascioli also inked a non-disclosure agreement. Anika denied all wrongdoing in a note filed with the SEC.

Today, Anika said it triggered a $5 million milestone payment after its hyaluronic acid-based osteoarthritis therapy, Monovisc, brought in $100 million in U.S. end-user sales within a consecutive 12-month period. The payment is a part of Anika’s license agreement with an unnamed U.S. commercial partner.

The company said it plans to account for this milestone payment as revenue in the second quarter of this year.

“This significant commercial milestone reflects a strong 12 months of growth in U.S. end-user demand for Monovisc, especially in the second quarter of 2017,” president & CEO Charles Sherwood said in prepared remarks. “We are proud of Monovisc’s growth and success in the U.S., and we remain focused on the global expansion of Monovisc to drive future growth.”

Anika also reported that it anticipates total revenue growth for the second quarter of this year to fall between 23% and 26% compared to the same period last year.

ANIK shares were trading at $46.97 apiece in morning activity today, up +1.1%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Legal News, Orthopedics, Pharmaceuticals, Wall Street Beat Tagged With: Anika Therapeutics Inc.

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS